Max
06-14-2002, 02:21 PM
Sea Sponge May Yield Arthritis Relief
Library: MED
Keywords: DRUG PATENT FOR MARINE DERIVATIVE IL
Description: The Professor of Pharmacology at Midwestern University, and a team of co-inventors in Florida recently secured a patent for a new anti-inflammatory agent that may one day be used in clinical settings for the treatment of diseases such as rheumatoid arthritis and osteoarthritis.
Alejandro M. S. Mayer, Ph.D., Professor of Pharmacology at Midwestern University, and a team of co-inventors in Florida recently secured a patent for a new anti-inflammatory agent that may one day be used in clinical settings for the treatment of diseases such as rheumatoid arthritis and osteoarthritis.
The agent, Manzamine A, is only the third drug in the U.S. Pharmacopeia that has been derived from marine natural products isolated from a sea sponge. The patent was issued by the U.S. Patent Office on May 14th, and is the culmination of five years of hard work, persistence, and determination. It is the first ever awarded to the University.
"We have shown that Manzamine A is a potent anti-inflammatory agent in our laboratory," said Dr. Mayer, "and are hopeful that it will someday become a novel clinical agent used to treat the many millions who are affected by rheumatoid arthritis, juvenile rheumatoid arthritis, and osteoarthritis."
###
Library: MED
Keywords: DRUG PATENT FOR MARINE DERIVATIVE IL
Description: The Professor of Pharmacology at Midwestern University, and a team of co-inventors in Florida recently secured a patent for a new anti-inflammatory agent that may one day be used in clinical settings for the treatment of diseases such as rheumatoid arthritis and osteoarthritis.
Alejandro M. S. Mayer, Ph.D., Professor of Pharmacology at Midwestern University, and a team of co-inventors in Florida recently secured a patent for a new anti-inflammatory agent that may one day be used in clinical settings for the treatment of diseases such as rheumatoid arthritis and osteoarthritis.
The agent, Manzamine A, is only the third drug in the U.S. Pharmacopeia that has been derived from marine natural products isolated from a sea sponge. The patent was issued by the U.S. Patent Office on May 14th, and is the culmination of five years of hard work, persistence, and determination. It is the first ever awarded to the University.
"We have shown that Manzamine A is a potent anti-inflammatory agent in our laboratory," said Dr. Mayer, "and are hopeful that it will someday become a novel clinical agent used to treat the many millions who are affected by rheumatoid arthritis, juvenile rheumatoid arthritis, and osteoarthritis."
###